Loading
Replacing vinblastine with etoposide in cisplatin-based chemotherapy for testicular cancer cured as many men with far less nerve and muscle toxicity and improved survival in advanced disease, establishing the BEP regimen used ever since.
Phase 3 trial of 261 men with disseminated germ cell tumours randomised to cisplatin, bleomycin and vinblastine (PVB) or cisplatin, bleomycin and etoposide (BEP).
Complete response rates were similar (74 versus 83 percent), but BEP caused less neuromuscular toxicity, and in patients with advanced disease it gave higher disease-free and overall survival.
BEP has been the backbone of curative chemotherapy for testicular cancer for nearly forty years.
Shares Non-seminomatous germ cell tumour, Bleomycin, Etoposide, Cisplatin.
Shares Non-seminomatous germ cell tumour, Bleomycin, Etoposide, Cisplatin.
Shares Non-seminomatous germ cell tumour, Bleomycin, Etoposide, Cisplatin.
Shares Non-seminomatous germ cell tumour, Bleomycin, Etoposide, Cisplatin.
Shares Etoposide, New England Journal of Medicine, Cisplatin.
Shares Non-seminomatous germ cell tumour, Bleomycin, Etoposide, Cisplatin.